Chinese CRO firm PharmaLegacy nets nearly $100m

Chinese contract development organisation PharmaLegacy has received approximately $100 million in a fresh round of financing.

The new round was co-led by return investors namely Sequoia Capital China and Hillhouse Capital’s GL Ventures. Other existing backers who joined the round include Prosperico Ventures and Med-Fine Capital. 

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter